SCHEMBL23256882

SCHEMBL23256882

N#Cc1cccc(NC(=O)Nc2nc3ccc(F)cc3s2)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DYRK1A Q13627 5/20 0.58
▸ DYRK1B Q9Y463 2/20 0.58
▸ NSD2 O96028 1/20 0.55
▸ PDPK1 O15530 1/20 0.55
▸ LRRK2 Q5S007 1/20 0.54
▸ NPC1 O15118 8/20 0.53
▸ RAB9A P51151 8/20 0.53
▸ KMT2A Q03164 6/20 0.53
▸ MEN1 O00255 5/20 0.53
▸ ADORA2A P29274 1/20 0.53
▸ ADORA1 P30542 1/20 0.53
▸ BLM P54132 1/20 0.53
▸ MAPT P10636 6/20 0.52
▸ ALDH1A1 P00352 2/20 0.52
▸ SMN1; SMN2 Q16637 5/20 0.51
▸ POLB P06746 4/20 0.51
▸ NFKB1 P19838 3/20 0.51
▸ NFKB2 Q00653 3/20 0.51
▸ RELA Q04206 3/20 0.51
▸ KDM4E B2RXH2 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23256883 0.91 DYRK1A (0.66) DYRK1ADYRK1BNSD2NPC1RAB9A
SCHEMBL23256872 0.87 HSD17B10 (0.61) DYRK1ADYRK1BNSD2NPC1RAB9A
SCHEMBL21568167 0.87 MEN1 (0.60) DYRK1ADYRK1BNSD2NPC1RAB9A
SCHEMBL21568324 0.87 DYRK1A (0.58) DYRK1ADYRK1BNSD2NPC1RAB9A
SCHEMBL21568062 0.87 DYRK1A (0.58) DYRK1ADYRK1BNSD2NPC1RAB9A
SCHEMBL21568288 0.87 DYRK1A (0.55) DYRK1ADYRK1BNSD2PDPK1NPC1
SCHEMBL21568137 0.86 MAPT (0.68) DYRK1ADYRK1BNSD2NPC1RAB9A
SCHEMBL23256548 0.86 CSNK1D (0.61) DYRK1ADYRK1BNSD2KMT2AMEN1
SCHEMBL21568954 0.86 DYRK1A (0.66) DYRK1ADYRK1BNSD2NPC1RAB9A
SCHEMBL31637674 0.86 HSD17B10 (0.61) DYRK1ADYRK1BNSD2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11731985-B2 Compositions and methods for treating cancer HB THERAPEUTICS INC. (US) 2023-08-22 — — US disclosed
US-11731985-B2 Compositions and methods for treating cancer HB THERAPEUTICS INC. (US) 2023-08-22 — — US disclosed
US-20210115064-A1 COMPOSITIONS AND METHODS FOR TREATING CANCER HB THERAPEUTICS INC. (US) 2021-04-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11731985-B2 Compositions and methods for treating cancer VHL, TP53, NUDT1 DYRK1A 4664/4885DYRK1B 4707/4885NSD2 378/4885
US-20210115064-A1 COMPOSITIONS AND METHODS FOR TREATING CANCER VHL, TP53, NUDT1 DYRK1A 4618/4885DYRK1B 4647/4885NSD2 501/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback